Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVALDI Praxis
ISRCTN18801971Phase 4Completed
- Sponsor
- Servier
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Servier. Primary endpoints: Change in depressive symptoms, Quality of life and patient satisfaction and 5 more. Started Jan 2010; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN18801971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18801971.